Recent News
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Publication Date March 05, 2010
CAMBRIDGE, Mass. - March 5, 2010. Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases.
Peptimmune Presentation at the upcoming meeting of the American Society for Experimental NeuroTherapeutics
Publication Date March 05, 2010
Dr. Zanelli will discuss the application of Peptimmune's DEEP technology to the development of a first-line disease modifying treatment for Parkinson's Disease.
Peptimmune to Collaborate on Dengue Virus Vaccine and Point-of-Care Diagnostic with two DOD biomedical research facilities
Publication Date September 24, 2009
Cambridge, Mass. Peptimmune, Inc. announced today that it has formed a research and development collaboration with the Walter Reed Army Institute of Research (WRAIR) and the Naval Medical Research Center (NMRC), Silver Spring, MD to evaluate the Company's proprietary DEEPTM peptide copolymer technology for the potential development of Dengue vaccines and point-of-care diagnostics.
Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients
Publication Date August 25, 2009
CAMBRIDGE, Mass. - Peptimmune announced today the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.
Peptimmune Featured in French Magazine, Biotech.Info
Publication Date February 25, 2009
Peptimmune modulates the immune system
